133 related articles for article (PubMed ID: 11007512)
1. Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma.
Kwekkeboom DJ; Bakker WH; Kooij PP; Erion J; Srinivasan A; de Jong M; Reubi JC; Krenning EP
Eur J Nucl Med; 2000 Sep; 27(9):1312-7. PubMed ID: 11007512
[TBL] [Abstract][Full Text] [Related]
2. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
[TBL] [Abstract][Full Text] [Related]
3. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
4. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo.
Reubi JC; Waser B; Schaer JC; Laederach U; Erion J; Srinivasan A; Schmidt MA; Bugaj JE
Eur J Nucl Med; 1998 May; 25(5):481-90. PubMed ID: 9575243
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
de Jong M; Bakker WH; Bernard BF; Valkema R; Kwekkeboom DJ; Reubi JC; Srinivasan A; Schmidt M; Krenning EP
J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889
[TBL] [Abstract][Full Text] [Related]
6. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
7. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
8. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.
Behr TM; Jenner N; Radetzky S; Béhe M; Gratz S; Yücekent S; Raue F; Becker W
Eur J Nucl Med; 1998 Apr; 25(4):424-30. PubMed ID: 9553173
[TBL] [Abstract][Full Text] [Related]
9. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas.
Reubi JC; Waser B
Int J Cancer; 1996 Sep; 67(5):644-7. PubMed ID: 8782652
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeling approaches for cholecystokinin B receptor imaging.
Aloj L; Panico MR; Caracó C; Zannetti A; Del Vecchio S; Di Nuzzo C; Arra C; Morelli G; Tesauro D; De Luca S; Pedone C; Salvatore M
Biopolymers; 2002; 66(6):370-80. PubMed ID: 12658724
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
Fröberg AC; de Jong M; Nock BA; Breeman WA; Erion JL; Maina T; Verdijsseldonck M; de Herder WW; van der Lugt A; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1265-72. PubMed ID: 19266197
[TBL] [Abstract][Full Text] [Related]
12. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
Kurtaran A; Leimer M; Kaserer K; Yang Q; Angelberger P; Niederle B; Virgolini I
Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging.
Aloj L; Panico M; Caraco C; Del Vecchio S; Arra C; Affuso A; Accardo A; Mansi R; Tesauro D; De Luca S; Pedone C; Visentin R; Mazzi U; Morelli G; Salvatore M
Cancer Biother Radiopharm; 2004 Feb; 19(1):93-8. PubMed ID: 15068617
[TBL] [Abstract][Full Text] [Related]
15. [The use of a new analogue DGlu-Octagastrin in scintigraphy of medullary thyroid carcinoma].
Kosowicz J; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Endokrynol Pol; 2006; 57(4):427-30. PubMed ID: 17006848
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody.
Barbet J; Peltier P; Bardet S; Vuillez JP; Bachelot I; Denet S; Olivier P; Leccia F; Corcuff B; Huglo D; Proye C; Rouvier E; Meyer P; Chatal JF
J Nucl Med; 1998 Jul; 39(7):1172-8. PubMed ID: 9669389
[TBL] [Abstract][Full Text] [Related]
17. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
[TBL] [Abstract][Full Text] [Related]
19. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
Bernà L; Chico A; Matías-Guiu X; Mato E; Catafau A; Alonso C; Mora J; Mauricio D; Rodríguez-Espinosa J; Marí C; Flotats A; Martín JC; Estorch M; Carrió I
Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
[TBL] [Abstract][Full Text] [Related]
20. Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma.
Blaker M; de Weerth A; Tometten M; Schulz M; Höppner W; Arlt D; Hoang-Vu C; Dralle H; Terpe H; Jonas L; von Schrenck T
Eur J Endocrinol; 2002 Jan; 146(1):89-96. PubMed ID: 11751073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]